Jefferies analyst Maury Raycroft reiterated a Buy rating and $52.00 price target on Ideaya Biosciences (NASDAQ: IDYA)

The analyst commented, "IDYA pushed back HLA- MUM pivotal topline from ~last wk of Mar to ~Apr, based on delays w/ data cleaning at 2 sites (1 ex-U.S. site is gating factor). Co expects database lock Apr 1-15, then ~2wks for full analysis. Mgmt said 130 BICR events were confirmed 1/23/26. Our simulation suggests ~90%+ chance for stat sig mPFS w/ 80% POS for mPFS >7. We believe IDYA could move up +10-30% w/ stat sig mPFS to support accel approval filing or down -50% on miss."

For an analyst ratings summary and ratings history on Ideaya Biosciences click here. For more ratings news on Ideaya Biosciences click here.

Shares of Ideaya Biosciences closed at $32.75 yesterday.